

Trans-NCI Pharmacogenomics and Pharmacoepidemiology Working Group (PPWG)

Andrew N. Freedman, PhD (DCCPS)

Arnie L. Potosky (DCCPS)

Leah Sansbury (DCCPS)

Lori Minasian, MD (DCP)

Heng Xie, MD, MPH (DCTD)


Claudio Dansky-Ullman (DCTD)

March 31, 2008

Trans-NCI Cancer Pharmacogenomics & Pharmacoepidemiology Working Group (PPWG)

- **Mission:**
 - Create a targeted cancer research agenda by evaluating epidemiologic, clinical trial and genomic information on adverse effects and enhanced response of antineoplastics and pharmaceuticals.

Trans-NCI PPWG



PPWG

- Basic Science Subgroup
 - Facilitate the development and application of PGx technologies for drug discovery and diagnostics development
 - Identify the most promising inter-individual PGx alterations that could be incorporated into clinical trials
- Clinical Trial Subgroup
 - Identify opportunities, resources, and methodologies needed for the incorporation and analysis of genetic biomarkers and tests in the design and analysis of clinical trials
 - Address the need to collect biological specimens for subsequent analyses of pharmacogenomic profiles

Population Sciences Subgroup

- Provide a platform to conduct targeted observational studies to:
 - Identify pharmacogenomic profiles related to short, intermediate, and long term adverse events, as well as enhanced response
 - Provide evidence for clinical utility of these profiles